Compare EPC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPC | NGNE |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.9M | 744.9M |
| IPO Year | 1999 | 2014 |
| Metric | EPC | NGNE |
|---|---|---|
| Price | $27.61 | $36.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $23.33 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 658.0K | 164.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,223,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.73 | $15.93 |
| 52 Week High | $29.95 | $43.66 |
| Indicator | EPC | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 56.17 |
| Support Level | $25.15 | $19.06 |
| Resistance Level | $28.01 | $43.66 |
| Average True Range (ATR) | 1.32 | 1.84 |
| MACD | -0.18 | -0.07 |
| Stochastic Oscillator | 56.27 | 86.67 |
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Wet Shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams. Sun and Skin Care consists of sun care products, men's and women's grooming products, Billie women's grooming products and personal wipe products. Feminine Care products include tampons, pads and liners. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.